Resource Summary Report

Generated by NIF on May 7, 2025

Sartorius IncuCyte S3 Live Cell Analysis System

RRID:SCR_023147
Type: Tool

Proper Citation

Sartorius IncuCyte S3 Live Cell Analysis System (RRID:SCR_023147)

Resource Information

URL: https://www.sartorius.com/en/products/live-cell-imaging-analysis/live-cell-analysis-instruments/s3-live-cell-analysis-instrument#id-797316

Proper Citation: Sartorius IncuCyte S3 Live Cell Analysis System (RRID:SCR_023147)

Description: System that automatically captures and analyzes images of living cells around-the-clock for days, weeks, or months, while cells remain undisturbed inside standard tissue culture incubator. Kinetic, image-based measurements. Used for cell monitoring and surveillance, cell health and viability, migration and invasion, phenotypic cell based assays.

Synonyms: Incucyte Live-Cell Analysis System, Incucyte S3 Live-Cell Analysis Instrument, Incucyte S3 System

Resource Type: instrument resource

Keywords: Instrument, Equipment, USEDit, Sartorius AG, living cells images, automatically capture and analyze images,

Funding:

Resource Name: Sartorius IncuCyte S3 Live Cell Analysis System

Resource ID: SCR_023147

Record Creation Time: 20230118T050205+0000

Record Last Update: 20250420T015242+0000

Ratings and Alerts

No rating or validation information has been found for Sartorius IncuCyte S3 Live Cell Analysis System.

No alerts have been found for Sartorius IncuCyte S3 Live Cell Analysis System.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Sun X, et al. (2025) Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer. Cancer research communications, 5(1), 119.

Gali A, et al. (2024) Protein kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. iScience, 27(2), 108958.

Mustafa EH, et al. (2024) Selective inhibition of CDK9 in triple negative breast cancer. Oncogene, 43(3), 202.

Willems M, et al. (2024) The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity. EBioMedicine, 109, 105418.

Greenwood A, et al. (2024) Cannabidiol promotes apoptosis and downregulation of oncogenic factors. bioRxiv : the preprint server for biology.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(15), 3298.

Schott CR, et al. (2024) Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(4), 849.

Springer AD, et al. (2024) Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma. Cancer research communications, 4(10), 2660.

Dorighi KM, et al. (2024) Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform. Cell reports, 43(6), 114313.

Cordova RA, et al. (2024) Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. Science signaling, 17(864), eadp1375.

Rosenbaum SR, et al. (2024) SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death. Molecular cancer research : MCR, 22(2), 209.

Konno T, et al. (2024) Endoplasmic reticulum morphology regulation by RTN4 modulates neuronal regeneration by curbing luminal transport. Cell reports, 43(7), 114357.

Sunshine HL, et al. (2024) Endothelial Jagged1 levels and distribution are post-transcriptionally controlled by ZFP36 decay proteins. Cell reports, 43(1), 113627.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell reports. Medicine, 4(8), 101142.

Subbiah V, et al. (2023) Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(16), 2988.

O'Brien S, et al. (2023) FBXW7-loss Sensitizes Cells to ATR Inhibition Through Induced Mitotic Catastrophe. Cancer research communications, 3(12), 2596.

Ramos L, et al. (2023) A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(17), 3541.

Vlassis A, et al. (2023) CRISPR-Cas12a-integrated transgenes in genomic safe harbors retain high expression in human hematopoietic iPSC-derived lineages and primary cells. iScience, 26(12), 108287.

Adaku N, et al. (2023) Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis. Cancer research, 83(18), 3013.

Wang X, et al. (2023) Identification of a ?Np63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Molecular cancer research : MCR, 21(9), 881.